LYKALABSPharmaceuticals
Lyka Labs Ltd — PE Ratio & Valuation Analysis
₹44.95
-9.04%
Current P/E139.58xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E21.7x544.7% above avg
⚠️
339.3% Premium to Industry
LYKALABS P/E 139.58x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹2.25 | ₹76 | 33.7x |
| 2022 | ₹13.57 | ₹130 | 9.6x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Lyka Labs Ltd Valuation
Lyka Labs Ltd (LYKALABS) currently trades at 139.58x earnings. The Pharmaceuticals sector average PE is 31.77x. LYKALABS commands a premium, reflecting high growth expectations. Historically, LYKALABS has traded at an average PE of 21.7x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
9.31%
Dividend Yield
0.00%
More on Lyka Labs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.